Nature Reviews Drug Discovery最新文献_第2页

Apolipoprotein L2 inhibitor mitigates fibrosis 载脂蛋白 L2 抑制剂可减轻纤维化

Nature Reviews Drug Discovery Pub Date : 2024-09-06 DOI: 10.1038/d41573-024-00139-8

引用次数: 0

Targeting the peripheral neural-tumour microenvironment for cancer therapy 针对外周神经-肿瘤微环境的癌症疗法

Nature Reviews Drug Discovery Pub Date : 2024-09-06 DOI: 10.1038/s41573-024-01017-z

Dan Yaniv, Brandi Mattson, Sebastien Talbot, Frederico O. Gleber-Netto, Moran Amit

{"title":"Targeting the peripheral neural-tumour microenvironment for cancer therapy","authors":"Dan Yaniv, Brandi Mattson, Sebastien Talbot, Frederico O. Gleber-Netto, Moran Amit","doi":"10.1038/s41573-024-01017-z","DOIUrl":"https://doi.org/10.1038/s41573-024-01017-z","url":null,"abstract":"<p>As the field of cancer neuroscience expands, the strategic targeting of interactions between neurons, cancer cells and other elements in the tumour microenvironment represents a potential paradigm shift in cancer treatment, comparable to the advent of our current understanding of tumour immunology. Cancer cells actively release growth factors that stimulate tumour neo-neurogenesis, and accumulating evidence indicates that tumour neo-innervation propels tumour progression, inhibits tumour-related pro-inflammatory cytokines, promotes neovascularization, facilitates metastasis and regulates immune exhaustion and evasion. In this Review, we give an up-to-date overview of the dynamics of the tumour microenvironment with an emphasis on tumour innervation by the peripheral nervous system, as well as current preclinical and clinical evidence of the benefits of targeting the nervous system in cancer, laying a scientific foundation for further clinical trials. Combining empirical data with a biomarker-driven approach to identify and hone neuronal targets implicated in cancer and its spread can pave the way for swift clinical integration.</p>","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding anellovirus immune evasion 了解无肠病毒的免疫逃避

Nature Reviews Drug Discovery Pub Date : 2024-09-06 DOI: 10.1038/d41573-024-00140-1

引用次数: 0

Protein isoform-centric therapeutics: expanding targets and increasing specificity 以蛋白质同工酶为中心的疗法：扩大靶点，提高特异性

Nature Reviews Drug Discovery Pub Date : 2024-09-04 DOI: 10.1038/s41573-024-01025-z

Peter Kjer-Hansen, Tri Giang Phan, Robert J. Weatheritt

{"title":"Protein isoform-centric therapeutics: expanding targets and increasing specificity","authors":"Peter Kjer-Hansen, Tri Giang Phan, Robert J. Weatheritt","doi":"10.1038/s41573-024-01025-z","DOIUrl":"https://doi.org/10.1038/s41573-024-01025-z","url":null,"abstract":"<p>Most protein-coding genes produce multiple protein isoforms; however, these isoforms are commonly neglected in drug discovery. The expression of protein isoforms can be specific to a disease, tissue and/or developmental stage, and this specific expression can be harnessed to achieve greater drug specificity than pan-targeting of all gene products and to enable improved treatments for diseases caused by aberrant protein isoform production. In recent years, several protein isoform-centric therapeutics have been developed. Here, we collate these studies and clinical trials to highlight three distinct but overlapping modes of action for protein isoform-centric drugs: isoform switching, isoform introduction or depletion, and modulation of isoform activity. In addition, we discuss how protein isoforms can be used clinically as targets for cell type-specific drug delivery and immunotherapy, diagnostic biomarkers and sources of cancer neoantigens. Collectively, we emphasize the value of a focus on isoforms as a route to discovering drugs with greater specificity and fewer adverse effects. This approach could enable the targeting of proteins for which pan-inhibition of all isoforms is toxic and poorly tolerated.</p>","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142130958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineered parasite delivers proteins to the brain 工程寄生虫向大脑输送蛋白质

Nature Reviews Drug Discovery Pub Date : 2024-08-23 DOI: 10.1038/d41573-024-00137-w

引用次数: 0

Degrading cell-free DNA to prevent recurrent stroke 降解无细胞 DNA 以预防中风复发

Nature Reviews Drug Discovery Pub Date : 2024-08-22 DOI: 10.1038/d41573-024-00136-x

引用次数: 0

FDA approves first TCR-engineered T cell therapy, for rare soft-tissue cancer FDA 批准首款 TCR 工程 T 细胞疗法，用于治疗罕见软组织癌症

Nature Reviews Drug Discovery Pub Date : 2024-08-16 DOI: 10.1038/d41573-024-00134-z

引用次数: 0

FDA approves IDH1 and IDH2 inhibitor for brain cancer 美国食品和药物管理局批准用于治疗脑癌的 IDH1 和 IDH2 抑制剂

Nature Reviews Drug Discovery Pub Date : 2024-08-16 DOI: 10.1038/d41573-024-00135-y

引用次数: 0

The breast cancer drug market 乳腺癌药物市场

Nature Reviews Drug Discovery Pub Date : 2024-08-13 DOI: 10.1038/d41573-024-00133-0

引用次数: 0

Chinese innovative drug R&D trends in 2024 2024 年中国创新药物研发趋势

Nature Reviews Drug Discovery Pub Date : 2024-07-31 DOI: 10.1038/d41573-024-00120-5

引用次数: 0